PUR Stock Overview
A biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł17.20 |
| 52 Week High | zł33.20 |
| 52 Week Low | zł6.35 |
| Beta | 1.47 |
| 1 Month Change | 4.12% |
| 3 Month Change | -17.90% |
| 1 Year Change | 36.08% |
| 3 Year Change | -79.28% |
| 5 Year Change | -52.09% |
| Change since IPO | -24.89% |
Recent News & Updates
Recent updates
Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn Situation
Dec 06
We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Aug 14Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?
Apr 30We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Jan 03We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow
Apr 21Shareholder Returns
| PUR | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 3.4% | 3.4% | 0.09% |
| 1Y | 36.1% | -24.5% | -4.7% |
Return vs Industry: PUR exceeded the Polish Biotechs industry which returned -25.3% over the past year.
Return vs Market: PUR exceeded the Polish Market which returned -4.5% over the past year.
Price Volatility
| PUR volatility | |
|---|---|
| PUR Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.9% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: PUR's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: PUR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 9 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PUR fundamental statistics | |
|---|---|
| Market cap | zł64.47m |
| Earnings (TTM) | -zł44.70m |
| Revenue (TTM) | n/a |
-6.1x
P/S Ratio-1.4x
P/E RatioIs PUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PUR income statement (TTM) | |
|---|---|
| Revenue | -zł10.52m |
| Cost of Revenue | zł2.67m |
| Gross Profit | -zł13.19m |
| Other Expenses | zł31.51m |
| Earnings | -zł44.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.92 |
| Gross Margin | 125.36% |
| Net Profit Margin | 424.91% |
| Debt/Equity Ratio | -273.6% |
How did PUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:49 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pure Biologics S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sylwia Jaskiewicz | Dom Maklerski Banku Ochrony Srodowiska S.A. |